These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22526548)

  • 21. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
    Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
    Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
    Fei F; Stoddart S; Groffen J; Heisterkamp N
    Mol Cancer Ther; 2010 May; 9(5):1318-27. PubMed ID: 20388735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
    Gizatullin F; Yao Y; Kung V; Harding MW; Loda M; Shapiro GI
    Cancer Res; 2006 Aug; 66(15):7668-77. PubMed ID: 16885368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.
    Eicher C; Dewerth A; Ellerkamp V; Fuchs J; Schott S; Armeanu-Ebinger S
    Pediatr Surg Int; 2013 Feb; 29(2):121-7. PubMed ID: 23187893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF; Kua N; Kaldis P; Lane DP
    Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
    Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
    Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.
    Glant TT; Besenyei T; Kádár A; Kurkó J; Tryniszewska B; Gál J; Soós G; Szekanecz Z; Hoffmann G; Block JA; Katz RS; Mikecz K; Rauch TA
    Arthritis Rheum; 2013 Jul; 65(7):1725-35. PubMed ID: 23653330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
    Lin ZZ; Hsu HC; Hsu CH; Yeh PY; Huang CY; Huang YF; Chen TJ; Kuo SH; Hsu C; Hu FC; Jeng YM; Chung Y; Cheng AL
    J Hepatol; 2009 Mar; 50(3):518-27. PubMed ID: 19155085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.
    Yao JE; Yan M; Guan Z; Pan CB; Xia LP; Li CX; Wang LH; Long ZJ; Zhao Y; Li MW; Zheng FM; Xu J; Lin DJ; Liu Q
    Mol Cancer; 2009 Nov; 8():95. PubMed ID: 19891769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
    Fu S; Li Y; Huang J; Liu T; Hong Z; Chen A; Bast RC; Kavanagh JJ; Gershenson DM; Sood AK; Hu W
    Cancer Biol Ther; 2012 Sep; 13(11):1034-41. PubMed ID: 22895067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro photodynamic therapy in pediatric epithelial liver tumors promoted by hypericin.
    Seitz G; Krause R; Fuchs J; Heitmann H; Armeanu S; Ruck P; Warmann SW
    Oncol Rep; 2008 Nov; 20(5):1277-82. PubMed ID: 18949433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.
    Harrington EA; Bebbington D; Moore J; Rasmussen RK; Ajose-Adeogun AO; Nakayama T; Graham JA; Demur C; Hercend T; Diu-Hercend A; Su M; Golec JM; Miller KM
    Nat Med; 2004 Mar; 10(3):262-7. PubMed ID: 14981513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Circumscribed Exposure to the Pan-Aurora Kinase Inhibitor VX-680 on Proliferating Euploid Cells.
    Liu X; Shi Q; Choudhry N; Zhang T; Liu H; Zhang S; Zhang J; Yang D
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
    Lieber J; Armeanu-Ebinger S; Fuchs J
    Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
    Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
    Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.